Navigation Links
MEDRAD, INC. Announces European Approval and Launch of the Cotavance™ Drug Eluting Balloon With Paccocath® Technology
Date:5/16/2011

he treatment of PAD is demonstrated by the initiation of randomized clinical studies examining the safety and performance of the Cotavance product for treating diseased arteries above and below the knee. Two of these studies, EURO CANAL and DEFINITIVE AR (sponsored by ev3 Inc., a Covidien company, using Cotavance catheters), are expected to begin enrolling patients this summer. Additionally, the COPA CABANA and RIVER studies will be initiated at a later date. Collectively, these studies will enroll more than 640 patients in approximately 90 sites around the world. Information from these studies is intended to expand the scientific evidence of the Cotavance catheter and Paccocath technology and should provide valuable data for the clinical community toward optimum care for patients suffering from PAD.

In addition to initiating clinical studies, MEDRAD is continuing to advance the technology of Cotavance paclitaxel-eluting balloon angioplasty catheters. MEDRAD is pursuing CE Mark certification for the next-generation Cotavance product with innovations that include enhanced drug dose application, a new catheter platform and a full range of catheter sizes. This advanced technology is expected to be available in Europe in the second half of 2011. The company is also moving forward with the Investigational Device Exemption (IDE) process as one of the steps in gaining FDA approval for Cotavance product in the United States.

"The European approval of the Cotavance catheter, preparation for its next-generation product launch, and initiation of additional randomized clinical studies underscore our commitment to further advancing peripheral arterial disease treatment, particularly as restenosis remains a significant issue for many patients," said Jack Darby, vice president of MEDRAD Interventional. "As a key participant in the endovascular market, MEDRAD is pleased to offer this treatment even as we actively pursue additional innovations and clinical studies with
'/>"/>

SOURCE MEDRAD, INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Telik Announces First Quarter 2011 Financial Results
2. Unilife Announces Financial Results for the Third Quarter of Fiscal 2011
3. Global Pharm Holdings Group Announces First Quarter 2011 Financial Results
4. Breckenridge Pharmaceutical Announces Settlement of Actos® (Pioglitazone Hydrochloride) Patent Litigation
5. Perrigo Announces FDA Final Approval for Ranitidine 150 - Generic Equivalent to Zantac 150®
6. UBM Canon Medical Device Content Team Announces Upcoming Virtual Event Content Topics
7. New Mexico Software Announces 2011 First Quarter Financial Results
8. Pacira Pharmaceuticals, Inc. Announces Phase 3 EXPAREL™ Data Presentation at the American Society of Colon and Rectal Surgeons 2011 Annual Meeting
9. Neurologix Announces First Quarter 2011 Financial Results
10. Naviscan Announces Partnership With Chindex Medical Limited for Mainland China, Hong Kong and Macau
11. China New Borun Announces First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Magnaquest, a leading Subscription ... cloud computing operators has signed a Proof of ... Internet of Things (IoT) related initiative. The PoC ... model.      (Logo: http://photos.prnewswire.com/prnh/20140807/700645 ) ... business innovations to make healthcare services more accessible ...
(Date:7/30/2015)...  ResMed Inc. (NYSE: RMD ) today announced ... for the quarter was $453.1 million, a 9 percent ... (a 17 percent increase on a constant currency basis). ... ended June 30, 2014.  Diluted earnings per share for ... June 30, 2014.  The results for ...
(Date:7/30/2015)... and VANCOUVER , July ... ) announced today that it will report its second ... Company management will host a conference call and live ... overview of financial results, clinical development programs and a ... webcast, log on to the Investor Relations page of ...
Breaking Medicine Technology:Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... MedImmune today announced,that it has initiated a Phase 1/2a ... children one month to 12 months of age to,help ... most common respiratory infection in infants and can cause ... a serious respiratory disease that can have significant effects,on ...
... Partner to Make Direct Investment in CEL-SCI, ... CVM ) announced today that it has expanded ... Co., Ltd. ("Orient,Europharma"), a leading pharmaceutical company from ... also cover South Korea,the Philippines, Australia and New ...
Cached Medicine Technology:MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine 2CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine 2CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine 3
(Date:7/31/2015)... Rochester, N.Y. (PRWEB) , ... July 31, 2015 ... ... Brand, is proud to announce that their latest designer handbag line will be ... recently become an Internet sensation as the first globally recognized model with Down ...
(Date:7/31/2015)... ... ... Ticket Down is a reputable source of authentic USA vs. Australia tickets at ... Women's National Team in conjunction with their Victory Tour to celebrate winning the 2015 Women's ... USA team was awarded the Golden Ball as the best player of the 2015 Women's ...
(Date:7/31/2015)... ... July 31, 2015 , ... Eldermark Software, the ... Center for Aging Services Technologies (CAST) Medication Management Technologies whitepaper. The whitepaper is ... providers understand the benefits of using medication management technologies . ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ZH Healthcare ... OSEHRA 2015. , What is HITaaS? Health IT as a Service (HITaaS) is a ... software as a service (SaaS). , HITaaS manages all aspects of ...
(Date:7/31/2015)... ... July 31, 2015 , ... Physical therapy for knee osteoarthritis is an ... life. It keeps the patient from doing what they want or need to do. The ... time using the stairs. The patient's exercise regime may be limited by the pain in ...
Breaking Medicine News(10 mins):Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 4Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3
... lacked this type of service within past year, study ... American teens don,t receive the appropriate amount of preventive ... establish good health behaviors and discourage damaging behaviors that ... a new study finds. , The University of California, ...
... Loss Costs Economy up to $15 Billion Each Year According ... than ever, Americans need their shut-eye. Unfortunately, sleep is usually ... is short and stress is high. In a turbulent economy, ... a few nights per week , according to a 2009 ...
... (Nasdaq: AMLN ) today announced its director ... Stockholders. Over the past several months, the Company,s Corporate ... in a rigorous process to identify a slate of ... believes will best serve the interests of all Amylin ...
... SAN DIEGO, March 30 NuVasive, Inc. (Nasdaq: ... developing products for minimally disruptive surgical treatments for the ... of the supply of Osteocel, NuVasive has accelerated the ... Therapeutics (Nasdaq: OSIR ) to its own ...
... Including Completing CE Mark, Application for ... (TSXV: NVC) today announced that it intends to undertake ... at the price of $0.21 per unit for aggregate ... offering will be used for continued development of a ...
... (Nasdaq: LCAV ), a leading provider of ... brand, today announced that, according to a March 26, ... dissident Joffe Group announced it has terminated its solicitation ... Group has disbanded. Additionally, the Joffe Group stated ...
Cached Medicine News:Health News:Most Teens Aren't Getting Preventive Health Care 2Health News:It Pays to Sleep: Prioritize Rest to Boost Health, Morale and Revenue 2Health News:It Pays to Sleep: Prioritize Rest to Boost Health, Morale and Revenue 3Health News:Amylin Pharmaceuticals Announces Slate of Directors for Annual Meeting of Stockholders 2Health News:Amylin Pharmaceuticals Announces Slate of Directors for Annual Meeting of Stockholders 3Health News:Amylin Pharmaceuticals Announces Slate of Directors for Annual Meeting of Stockholders 4Health News:Long Term Supply of Osteocel(R) Plus Solidified Without Ownership of Processing Facility 2Health News:Long Term Supply of Osteocel(R) Plus Solidified Without Ownership of Processing Facility 3Health News:Long Term Supply of Osteocel(R) Plus Solidified Without Ownership of Processing Facility 4Health News:Neovasc to Raise $2 Million in Non-Brokered Private Placement 2Health News:Neovasc to Raise $2 Million in Non-Brokered Private Placement 3Health News:LCA-Vision Announces Termination of Consent Solicitation and Withdrawal of Dissident Slate of Director Nominees 2
... Reusable Purstring Device for use ... Biofragmentable Anastomosis Ring)., ,The ... intestinal, colorectal and esophageal surgery ... string sutures and is intended ...
The Auto Suture™ EEA™ 34mm reusable stainless steel sizer has application in intestinal, colorectal and esophageal surgery to help evaluate the diameter of tubular structures....
... Scantibodies Calcitonin Immunoassay is a two-site immunoradiometric ... Two different goat polyclonal antibodies to human ... to be specific for well-defined regions on ... determination of Calcitonin in human serum. ...
Fully automated Chemiluminescence assay for the measurement of calcitonin hormone in serum....
Medicine Products: